Education
About Us
Working with TipRanks
Follow Us
Guided Therapeutics Inc (GTHP)
OTHER OTC:GTHP
Total Valuation
Guided Therapeutics has a market cap or net worth of $11.17M. The enterprise value is $11.64M.
Market Cap$11.17M
Enterprise Value$11.64M
Share Statistics
Guided Therapeutics has 78,910,180 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding78,910,180
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Guided Therapeutics’s return on equity (ROE) is 0.49 and return on invested capital (ROIC) is 86.12%.
Return on Equity (ROE)0.49
Return on Assets (ROA)-1.75
Return on Invested Capital (ROIC)86.12%
Return on Capital Employed (ROCE)0.44
Revenue Per Employee1.75K
Profits Per Employee-604.25K
Employee Count4
Asset Turnover<0.01
Inventory Turnover0.16
Valuation Ratios
The current PE Ratio of Guided Therapeutics is -3.56. Guided Therapeutics’s PEG ratio is 0.54.
PE Ratio-3.56
PS Ratio0.00
PB Ratio9.80
Price to Fair Value-1.76
Price to FCF-7.22
Price to Operating Cash Flow-6.32
PEG Ratio0.54
Income Statement
In the last 12 months, Guided Therapeutics had revenue of 7.00K and earned -2.42M in profits. Earnings per share was -0.05.
Revenue7.00K
Gross Profit2.00K
Operating Income-2.11M
Pretax Income-2.42M
Net Income-2.42M
EBITDA-1.94M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -1.35M and capital expenditures 0.00, giving a free cash flow of -1.35M billion.
Operating Cash Flow-1.35M
Free Cash Flow-1.35M
Free Cash Flow per Share-0.02
Dividends & Yields
Guided Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.61
52-Week Price Change88.89%
50-Day Moving Average0.10
200-Day Moving Average0.13
Relative Strength Index (RSI)68.08
Average Volume (3m)5.63K
Important Dates
Guided Therapeutics upcoming earnings date is Nov 13, 2023, TBA Not Confirmed.
Last Earnings DateAug 15, 2023
Next Earnings DateNov 13, 2023
Ex-Dividend Date―
Financial Position
Guided Therapeutics as a current ratio of 0.19, with Debt / Equity ratio of 230.88%
Current Ratio0.19
Quick Ratio0.09
Debt to Market Cap0.25
Net Debt to EBITDA-0.91
Interest Coverage Ratio-5.53
Taxes
In the past 12 months, Guided Therapeutics has paid 174.00K in taxes.
Income Tax174.00K
Effective Tax Rate-0.07
Enterprise Valuation
Guided Therapeutics EV to EBITDA ratio is -5.34, with an EV/FCF ratio of -9.27.
EV to Sales1.48K
EV to EBITDA-5.34
EV to Free Cash Flow-9.27
EV to Operating Cash Flow-9.27
Balance Sheet
Guided Therapeutics has $115.00K in cash and marketable securities with $2.01M in debt, giving a net cash position of $1.90M billion.
Cash & Marketable Securities$115.00K
Total Debt$2.01M
Net Cash$1.90M
Net Cash Per Share$0.02
Tangible Book Value Per Share-$0.09
Margins
Gross margin is -525.00%, with operating margin of -30114.29%, and net profit margin of -34528.57%.
Gross Margin-525.00%
Operating Margin-30114.29%
Pretax Margin-34528.57%
Net Profit Margin-34528.57%
EBITDA Margin-27728.57%
EBIT Margin-29085.71%
Analyst Forecast
The average price target for Guided Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―